Patent 11566245 was granted and assigned to Ionis Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.
The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.